2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH

Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd

NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy. *Numerical reduction in syndesmophytes 11% vs. 25% Abs#0546 @RheumNow #ACR22 #ACRBest https://t.co/pG5F3xdsh9

Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip

#Abstr 0545 GO-BACK Trial Continue vs Withdrawal of GOL in nr-axSpA with inactive disease - Full tx withdrawal associated w/ dx flare - Re-treatment -->rapid clinical response after flare - qMonthly tx --> higher rates of disease activity improvement @RheumNow #ACR22 https://t.co/Z3bhA9D4RQ

P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares 📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL 📌Non-adj: antidsDNA+, antiSm+ addt'l predictors 🧐p alb & antiSm+ potential predictors? #ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe

Majority of pts withdrawn from IXE to PBO recaptured at least LDA & over half met ID w/ IXE retreatment. This may help us clinically with pts who have treatment interruptions. Abs 0427 #ACR22 @RheumNow https://t.co/m4c3P8l25m https://t.co/iQshG1oq2Y

The CONSUL trial by Dr Proft et al. compared impact of CEL+GOL vs. GOL alone on radiographic spinal progression in AS showed no significant difference bet. the 2 grps in mSASSS change after 108 wks. Risk stratify pts who will benefit from tx #ACR22 @RheumNow ABST#0546 #ACRBest https://t.co/jWwX7w85ur

Clinical pearl! First-line tx w/ bio-originator or biosimilar ADA/ETA showed similar effectiveness & safety in long-term cohort of axSpA pts. Response to treatment was also similar between groups. Abs 0431 #ACR22 @RheumNow https://t.co/bGGXk51hIG https://t.co/PSsX3MpSXt

Presenting our last (virtual) #JAKpot poster at #ACR22 1-3 pm ET (7-10 CET) in the RA treatment session. Does anyone know what we will are supposed to do? Stay in front of our computer for 2 hours? @rheum_cat @ProftDr @DrMiniDey @EMEUNET @KragstrupTW https://t.co/uCNMezmJ4V